^
Association details:
| Biomarker: | HR positive |
|---|---|
| Cancer: | HER2 Negative Breast Cancer |
| Drug: | birociclib (XZP 3287) (CDK4 inhibitor, CDK6 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
A Study of XZP-3287 in Combination With Letrozole/Anastrozole in Patients With Advanced Breast Cancer
Excerpt:
...Histologically or cytologically confirmed locally advanced, recurrent or metastatic breast cancer, which was pathologically confirmed to be HR-positive and HER2-negative; 4....
Trial ID:
Source:
Title:
A Study of XZP-3287 in Combination With Fulvestrant in Patients With Advanced Breast Cancer
Excerpt:
...Pathologically-confirmed HR positive and Her2 negative Breast Cancer; 4....
Trial ID:
More C2 evidence
Source:
Title:
A Phase I/II Study of XZP-3287 in Metastasis Solid Tumors
Excerpt:
...Combination dose exploration study：Patients with locally advanced or metastatic breast cancer with hormone receptor positive (HR+) and her2-negative (HER2-) were...
Trial ID:
Less C2 evidence
Source:
Title:
404P - A multicenter, single-arm, open-label trial of birociclib, a CDK4/6 inhibitor, as a single agent, in patients with refractory HR+/HER2- metastatic breast cancer
Published date:
10/16/2023
Excerpt:
This phase II study (NCT04539496) was to evaluate the efficacy and safety of birociclib as single-agent in patients with refractory HR+/HER2- metastatic breast cancer (MBC)….In patients with refractory HR+/HER2- MBC who have previously received chemotherapy and endocrine therapy, continuous dosing of single-agent birociclib exhibited promising and sustaining clinical activity with manageable toxicities, thus it provides an alternative orally single-agent therapy.
